Andreas Reiter

7.8k total citations
40 papers, 1.2k citations indexed

About

Andreas Reiter is a scholar working on Immunology, Rheumatology and Molecular Biology. According to data from OpenAlex, Andreas Reiter has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 10 papers in Rheumatology and 9 papers in Molecular Biology. Recurrent topics in Andreas Reiter's work include Mast cells and histamine (25 papers), Eosinophilic Disorders and Syndromes (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Andreas Reiter is often cited by papers focused on Mast cells and histamine (25 papers), Eosinophilic Disorders and Syndromes (6 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Andreas Reiter collaborates with scholars based in Germany, Austria and France. Andreas Reiter's co-authors include Peter Valent, Karl Sotlar, Donald Macdonald, Nicholas C.P. Cross, Cem Akin, Michel Arock, Jason Gotlib, Wolfgang R. Sperr, Karin Hartmann and Hans-Peter Horny and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Andreas Reiter

39 papers receiving 1.2k citations

Peers

Countries citing papers authored by Andreas Reiter

Since Specialization

Citations

This map shows the geographic impact of Andreas Reiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Reiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Reiter more than expected).

Fields of papers citing papers by Andreas Reiter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Reiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Reiter. The network helps show where Andreas Reiter may publish in the future.

Co-authorship network of co-authors of Andreas Reiter

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Reiter. A scholar is included among the top collaborators of Andreas Reiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Reiter. Andreas Reiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024 2025 ·Annals of Hematology ·Martin Grießhammer, Haifa Kathrin Al‐Ali, Jan‐Niklas Eckardt, Michael Fiegl, Joachim R. Göthert, Kathleen Jentsch‐Ullrich, Steffen Koschmieder, Hans Michael Kvasnicka, Andreas Reiter, Burkhard Schmidt, Florian H. Heidel	1
2	Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis 2025 ·British Journal of Haematology ·Johannes Lübke, Nicole Naumann, (unknown), (unknown), Roland Repp, Georgia Metzgeroth, Alice Fabarius, Wolf‐Karsten Hofmann, Deepti Radia, Andreas Reiter, Juliana Schwaab	1
3	Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts 2023 ·International Journal of Molecular Sciences ·Peter Valent, Cem Akin, Michel Arock, Karoline V. Gleixner, Hildegard Greinix, Olivier Hermine, Hans‐Peter Horny, (unknown), Alberto Órfão, Werner Rabitsch, Andreas Reiter, Axel Schulenburg, Karl Sotlar, Wolfgang R. Sperr, Celalettin Üstün	1
4	Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders? 2022 ·Journal of Allergy and Clinical Immunology ·Peter Valent, Cem Akin, Karin Hartmann, Andreas Reiter, Jason Gotlib, Karl Sotlar, Wolfgang R. Sperr, (unknown), (unknown), Massimo Triggiani, Hans‐Peter Horny, Michel Arock, Stephen J. Galli, Dean D. Metcalfe	17
5	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022 2022 ·Journal of Allergy and Clinical Immunology ·Michel Arock, Gregor Hoermann, Karl Sotlar, Olivier Hermine, Wolfgang R. Sperr, Karin Hartmann, Knut Brockow, Cem Akin, Massimo Triggiani, Sigurd Broesby‐Olsen, Andreas Reiter, Jason Gotlib, Hans‐Peter Horny, Alberto Órfão, Dean D. Metcalfe, Peter Valent	22
6	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis 2020 ·Journal of Allergy and Clinical Immunology ·Karin Hartmann, Jason Gotlib, Cem Akin, Olivier Hermine, Farrukh T. Awan, Elizabeth O. Hexner, Michael J. Mauro, Hans D. Menssen, Suman Redhu, (unknown), Karl Sotlar, Tracy I. George, Hans-Peter Horny, Peter Valent, Andreas Reiter, Hanneke C. Kluin‐Nelemans	38
7	Identification of a leukemia-initiating stem cell in human mast cell leukemia 2019 ·Leukemia ·Gregor Eisenwort, Irina Sadovnik, Juliana Schwaab, Mohamad Jawhar, Alexandra Keller, Gabriele Stefanzl, Daniela Berger, Katharina Blatt, Gregor Hoermann, Martin Bilban, Michael Willmann, (unknown), Wolfgang R. Sperr, Michel Arock, Thomas Rülicke, Andreas Reiter, Peter Valent	15
8	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches 2019 ·International Journal of Molecular Sciences ·Peter Valent, Cem Akin, Karoline V. Gleixner, Wolfgang R. Sperr, Andreas Reiter, Michel Arock, Massimo Triggiani	51
9	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis 2018 ·Haematologica ·Mathias Schneeweiss‐Gleixner, Barbara Peter, (unknown), Gregor Eisenwort, (unknown), Katharina Blatt, Mohamad Jawhar, Daniela Berger, Gabriele Stefanzl, Susanne Herndlhofer, Georg Greiner, Gregor Hoermann, Emir Hadzijusufovic, Karoline V. Gleixner, Peter Bettelheim, Klaus Geißler, Wolfgang R. Sperr, Andreas Reiter, Michel Arock, Peter Valent	26
10	Midostaurin: a magic bullet that blocks mast cell expansion and activation 2017 ·Annals of Oncology ·Peter Valent, Cem Akin, Karin Hartmann, Tracy I. George, Karl Sotlar, Barbara Peter, Karoline V. Gleixner, K. Blatt, Wolfgang R. Sperr, Paul W. Manley, Olivier Hermine, Hanneke C. Kluin‐Nelemans, Michel Arock, H.-P. Horny, Andreas Reiter, Jason Gotlib	44
11	Development and Content Validity of the Advanced Systemic Mastocytosis Symptom Assessment Form (ADVSM-SAF) 2016 ·Value in Health ·(unknown), Erica N Evans, Fiona Taylor, (unknown), (unknown), (unknown), H.‐P. Horny, Andreas Reiter, Jason Gotlib, Alan L. Shields	2
12	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis 2016 ·New England Journal of Medicine ·Jason Gotlib, Hanneke C. Kluin‐Nelemans, Tracy I. George, Cem Akin, Karl Sotlar, Olivier Hermine, Farrukh T. Awan, Elizabeth O. Hexner, Michael J. Mauro, David Sternberg, Matthieu Villeneuve, Alice Huntsman Labed, Eric J. Stanek, Karin Hartmann, Hans-Peter Horny, Peter Valent, Andreas Reiter	284
13	Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity 2015 ·Journal of Allergy and Clinical Immunology ·Anja Rabenhorst, (unknown), Juliana Schwaab, Manuela Gehring, Anja Förster, Michel Arock, Andreas Reiter, Ulrike Raap, Karin Hartmann	14
14	The serum tryptase test: an emerging robust biomarker in clinical hematology 2014 ·Expert Review of Hematology ·Peter Valent, Wolfgang R. Sperr, Karl Sotlar, Andreas Reiter, Cem Akin, Jason Gotlib, Hans-Peter Horny, Michel Arock	51
15	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V 2013 ·Haematologica ·Karoline V. Gleixner, Barbara Peter, K. Blatt, (unknown), Andreas Reiter, Deepti Radia, Emir Hadzijusufovic, Peter Valent	37
16	Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma 2012 ·Leukemia Research ·Christoph Walz, Marion Subklewe, Hans‐Peter Horny, Michael J. Flaig, Andreas Reiter, Thomas Kirchner, Karl Sotlar	1
17	A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). 2011 ·Journal of Clinical Oncology ·Jason Gotlib, Hanneke C. Kluin‐Nelemans, Michael J. Mauro, Olivier Hermine, Elizabeth O. Hexner, J. H. Lipton, Farrukh T. Awan, Zariana Nikolova, (unknown), Catherine Dutreix, B. Dharan, (unknown), (unknown), Cem Akin, Katrin Hartmann, Peter Valent, Andreas Reiter, (unknown)	2
18	The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of <i>FGFR1</i> 2002 ·Acta Haematologica ·Donald Macdonald, Andreas Reiter, Nicholas C.P. Cross	142
19	Transgalactosylation by thermostable β‐glycosidases from Pyrococcus furiosus and Sulfolobus solfataricus 2000 ·European Journal of Biochemistry ·(unknown), Andreas Reiter, Barbara Splechtna, Paul Kosma, Bernd Nidetzky	45
20	Synthesis of Pseudomonasaeruginosa lipopolysaccharide core antigens containing 7-O-carbamoyl-l-glycero-α-d-manno-heptopyranosyl residues 1999 ·Carbohydrate Research ·Andreas Reiter, Alla Zamyatina, (unknown), Andreas Hofinger, Paul Kosma	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact